Cargando…

Development of advantus™(imidacloprid) soft chewable tablets for the treatment of Ctenocephalides felis infestations on dogs

BACKGROUND: Studies reported here were conducted to evaluate the safety and effectiveness of advantus™ (imidacloprid) soft chewable tablets for the treatment of flea (Ctenocephalides felis) infestations on dogs and puppies 10 weeks of age or older and weighing 4 pounds or greater. METHODS: A pharmac...

Descripción completa

Detalles Bibliográficos
Autores principales: Qureshi, Tariq, Everett, William R., Palma, Kathleen G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524436/
https://www.ncbi.nlm.nih.gov/pubmed/26238246
http://dx.doi.org/10.1186/s13071-015-1020-1
_version_ 1782384195103883264
author Qureshi, Tariq
Everett, William R.
Palma, Kathleen G.
author_facet Qureshi, Tariq
Everett, William R.
Palma, Kathleen G.
author_sort Qureshi, Tariq
collection PubMed
description BACKGROUND: Studies reported here were conducted to evaluate the safety and effectiveness of advantus™ (imidacloprid) soft chewable tablets for the treatment of flea (Ctenocephalides felis) infestations on dogs and puppies 10 weeks of age or older and weighing 4 pounds or greater. METHODS: A pharmacokinetic study was conducted to evaluate parameters of orally administered imidacloprid. A dose confirmation study was conducted to confirm the efficacy of 0.75 mg/kg at 8, 12 or 24 hours post-treatment. A knockdown and speed of kill study was conducted to confirm the efficacy of 0.75 mg/kg dose at 0.5, 1, 4 or 24 hours post-treatment. The safety of a daily dose administered for six months at approximately 1, 3, and 5 times the maximum exposure dose of 3.75 mg/kg was evaluated in puppies. A field study was conducted to evaluate the safety and efficacy of a daily oral dose of 0.75 mg/kg for 14 days in client-owned dogs. RESULTS: The pharmacokinetic parameters of the final imidacloprid oral formulation were; T(max) 1.31 hours, C(max) 690.0 ng/mL, AUC 2615.5 h*ng/mL and half-life was 2.2 hours. The efficacy of 0.75 mg/kg BW was 98.6 %, 99.9 % and 100 % at 8, 12 and 24 hours post-treatment, respectively. The live flea counts were significantly different (p < 0.0001) and the treatment was well tolerated. The flea counts at 1 hour post-treatment were significantly lower in the treated group and the speed of kill efficacy was 96.6 % at 4 hours post-treatment in the knockdown and speed of kill study. The target animal safety study showed that the advantus™ soft chewable tablets administered orally to 10-week-old puppies once daily for 6 months at approximately 1, 3 and 5 times the maximum dose of 3.75 mg/kg was well tolerated and did not produce clinically relevant findings in Beagles. In the field study, efficacy of the soft chewable tablets administered daily for 14 days to flea-infested dogs was 98.2 %. CONCLUSION: Imidacloprid administered orally as a soft chewable tablet for the treatment of fleas on dogs was safe and highly effective with a rapid knockdown effect and rapid elimination.
format Online
Article
Text
id pubmed-4524436
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45244362015-08-05 Development of advantus™(imidacloprid) soft chewable tablets for the treatment of Ctenocephalides felis infestations on dogs Qureshi, Tariq Everett, William R. Palma, Kathleen G. Parasit Vectors Research BACKGROUND: Studies reported here were conducted to evaluate the safety and effectiveness of advantus™ (imidacloprid) soft chewable tablets for the treatment of flea (Ctenocephalides felis) infestations on dogs and puppies 10 weeks of age or older and weighing 4 pounds or greater. METHODS: A pharmacokinetic study was conducted to evaluate parameters of orally administered imidacloprid. A dose confirmation study was conducted to confirm the efficacy of 0.75 mg/kg at 8, 12 or 24 hours post-treatment. A knockdown and speed of kill study was conducted to confirm the efficacy of 0.75 mg/kg dose at 0.5, 1, 4 or 24 hours post-treatment. The safety of a daily dose administered for six months at approximately 1, 3, and 5 times the maximum exposure dose of 3.75 mg/kg was evaluated in puppies. A field study was conducted to evaluate the safety and efficacy of a daily oral dose of 0.75 mg/kg for 14 days in client-owned dogs. RESULTS: The pharmacokinetic parameters of the final imidacloprid oral formulation were; T(max) 1.31 hours, C(max) 690.0 ng/mL, AUC 2615.5 h*ng/mL and half-life was 2.2 hours. The efficacy of 0.75 mg/kg BW was 98.6 %, 99.9 % and 100 % at 8, 12 and 24 hours post-treatment, respectively. The live flea counts were significantly different (p < 0.0001) and the treatment was well tolerated. The flea counts at 1 hour post-treatment were significantly lower in the treated group and the speed of kill efficacy was 96.6 % at 4 hours post-treatment in the knockdown and speed of kill study. The target animal safety study showed that the advantus™ soft chewable tablets administered orally to 10-week-old puppies once daily for 6 months at approximately 1, 3 and 5 times the maximum dose of 3.75 mg/kg was well tolerated and did not produce clinically relevant findings in Beagles. In the field study, efficacy of the soft chewable tablets administered daily for 14 days to flea-infested dogs was 98.2 %. CONCLUSION: Imidacloprid administered orally as a soft chewable tablet for the treatment of fleas on dogs was safe and highly effective with a rapid knockdown effect and rapid elimination. BioMed Central 2015-08-04 /pmc/articles/PMC4524436/ /pubmed/26238246 http://dx.doi.org/10.1186/s13071-015-1020-1 Text en © Qureshi et al. 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Qureshi, Tariq
Everett, William R.
Palma, Kathleen G.
Development of advantus™(imidacloprid) soft chewable tablets for the treatment of Ctenocephalides felis infestations on dogs
title Development of advantus™(imidacloprid) soft chewable tablets for the treatment of Ctenocephalides felis infestations on dogs
title_full Development of advantus™(imidacloprid) soft chewable tablets for the treatment of Ctenocephalides felis infestations on dogs
title_fullStr Development of advantus™(imidacloprid) soft chewable tablets for the treatment of Ctenocephalides felis infestations on dogs
title_full_unstemmed Development of advantus™(imidacloprid) soft chewable tablets for the treatment of Ctenocephalides felis infestations on dogs
title_short Development of advantus™(imidacloprid) soft chewable tablets for the treatment of Ctenocephalides felis infestations on dogs
title_sort development of advantus™(imidacloprid) soft chewable tablets for the treatment of ctenocephalides felis infestations on dogs
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524436/
https://www.ncbi.nlm.nih.gov/pubmed/26238246
http://dx.doi.org/10.1186/s13071-015-1020-1
work_keys_str_mv AT qureshitariq developmentofadvantusimidaclopridsoftchewabletabletsforthetreatmentofctenocephalidesfelisinfestationsondogs
AT everettwilliamr developmentofadvantusimidaclopridsoftchewabletabletsforthetreatmentofctenocephalidesfelisinfestationsondogs
AT palmakathleeng developmentofadvantusimidaclopridsoftchewabletabletsforthetreatmentofctenocephalidesfelisinfestationsondogs